Dyax
This article was originally published in The Gray Sheet
Executive Summary
Exercise of a 600,000-share underwriter overallotment option increases initial public offering gross proceeds to $69 mil. All together, the biopharmaceutical company's IPO consisted of 4.6 mil. shares at $15 each (1"The Gray Sheet" Aug. 21, 2000, p. 11). J.P. Morgan & Co. was lead manager for the offering, with Lehman Brothers and Pacific Growth Equities acting as co-managers
You may also be interested in...
Dyax
Biopharmaceutical company prices initial public offering of 4 mil. shares at $15 each on Aug. 15. Cambridge, Massachusetts-based Dyax' phage display technology is being used to "identify a broad range of compounds with potential for the treatment and diagnosis of disease," the firm states. Proceeds from the IPO are tabbed for R&D, possible acquisitions and working capital. The issue trades on the Nasdaq exchange under the symbol "DYAX." J.P. Morgan, Lehman Brothers and Pacific Growth Equities managed the offering
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.